NeoGenomics reported solid financial metrics for Q1 2025, with total revenue reaching $168 million, representing an 8% increase compared to the same period last year. This growth was driven by an 8% ...

Fort Myers-based cancer testing and research lab NeoGenomics expects to report double-digit revenue growth for 2025. However, ...

NeoGenomics Inc . (NASDAQ:NEO) presented its second quarter 2025 financial results on July 29, revealing mixed performance that prompted a significant market reaction. The oncology diagnostics company ...

FORT MYERS, Fla., December 30, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the ...

Analyst Puneet Souda from Leerink Partners maintained a Buy rating on NeoGenomics (NEO – Research Report) and keeping the price target at $30.00. Puneet Souda has given his Buy rating due to a ...

NeoGenomics has announced a new CEO. The Fort Myers-based cancer testing and research lab, with a national footprint, shared the news Friday, via a press release. Chris Smith, the public company's ...

NeoGenomics, Inc. (NASDAQ:NEO) presented its first quarter 2025 financial results on April 29, 2025, showcasing a strong performance that marks a significant improvement following disappointing Q4 ...